sub:assertion {
d:DB00382 dv:ddi-interactor-in dr:DB00382_DB00752 .
d:DB00752 dv:ddi-interactor-in dr:DB00382_DB00752 .
dr:DB00382_DB00752 dcterms:identifier "drugbank_resource:DB00382_DB00752" ;
dcterms:title "DDI between Tacrine and Tranylcypromine - The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Tacrine and Tranylcypromine - The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. [drugbank_resource:DB00382_DB00752]"@en .
}